← All stories
Markets
TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study Transcript
Covered by 1 outlet
All coverage · 1 article